Abstract
Rapid advances in cancer gene therapy are driven by an explosive development of gene transfer technology and a strong demand for seeking alternatives to unsatisfactory conventional cancer therapies. Discovery of the genetic basis of cancer has indicated that cancer is a disease of genes. Among a variety of approaches to gene therapy of cancer, antisense oncogene and tumor suppressor gene therapy of cancer are the two strategies that aim at correcting genetic disorders of cancer through suppression of the abnormal expression of the proliferative genes. The potential effectiveness of these approaches is promised by their precise targeting at the mechanisms of the disease. Examples of several preclinical studies of these types of approaches that led to the approval of clinical trials are reviewed. Limitation and future development of these approaches are also discussed.
Similar content being viewed by others
References
Harris CC (1992) Molecular basis of multistage carcinogenesis. In: Harris CC, Hirohashi S, Ito N, Pitot HC, Sugimura T, Terada M, Yokota J (eds) Multistage carcinogenesis. Japan Scientific Society, Tokyo/CRC, Boca Raton, 3–19
Weinberg RA Brugge J, Curran T, Harlow ED, McCormick F, (1991) Oncogenes, tumor suppressor genes, and cell transformation: trying to put it all together. In: Brugge J, Curran T, Harlow ED, McCormick F (eds) Origins of human cancer: a comprehensive review. Cold Spring Harbor Laboratory, New York, 1–16
Zhang W-W, Fang X (1995) Gene therapy strategies for cancer. Exp Opin Invest Drugs 4:487–514
Herrmann F (1995) Cancer gene therapy: principles, problems, and perspectives. J Mol Med 73:157–163
Stein CA, Cohen JS (1988) Oligodeoxynucleotides as inhibitors of gene expression: a review. Cancer Res 48, 2659–2668
Hanvey JC, Peffer NJ, Bisi JE, Thompson SA, Cadilla R, Josey JA, Ricca DJ, Hassman CF, Bonham MA, Au KG, Carter SG, Bruckenstein DA, Boyd AL, Noble SA, Babiss LE (1992) Antisense and antigene properties of peptide nucleic acids. Science 258:1481–1485
Choo Y, Sanchez-Garcia I, Klung A (1994) In vivo repression by a site-specific DNA-binding protein designed against an oncogenic sequence. Nature 372:642–645
Mercola D, Cohen JS (1995) Antisense approaches to cancer gene therapy. Cancer Gene Ther 2:47–59
Crooke ST (1993) Oligonucleotide therapeutics: a prospectus. Antisense Res Develop 3:1–2
Wickstrom E (1986) Oligodeoxynucleotide stability in subcellular extracts and culture media. J Biochem Biophys Methods 13:97–102
Helene C (1991) Rational design of sequence-specific oncogene inhibitors based on antisense and antigene oligonucleotides. Eur J Cancer 27:1466–1471
Crooke RM (1991) In vitro toxicology and pharmacokinetics of antisense oligonucleotides. Anti-Cancer Drug Design 6:609–646
Prochownik EV, Erickson RP, Izant JG (1992) Antisense approaches to assessing oncogene signaling pathway. In: Erickson RP, Izant JG (eds) Gene regulation: biology of antisense RNA and DNA, vol 1, Raven, New York, 303–316
Stein CA, Cheng YC (1993) Antisense oligonucleotides as therapeutic agents-is the bullet really magical? Science 261:1004–1012
Szczylik C, Skorski T, Nicolaides NC, Manzella L, Malaguarnera L, Venturelli D, Gewirtz AM, Calabretta B (1991) Selective inhibition of leukemia cell proliferation by BCR-ABL antisense oligodeoxynucleotides. Science 253:562–565
Skorski T, Nieborowskaskorska M, Barletta C, Malaguarnera L, Szczylik C, Chen ST, Lange B, Calabretta B (1993) Highly efficient elimination of Philadelphia leukemic cells by exposure to bcr/abl antosense oligodeoxynucleotides combined with mafosfamide. J Clin Invest 92:194–202
Akhtar S, Ivinson AJ (1993) Therapies that make sense. Nature Genet 4:215–217
Bayever E, Iversen P, Smith L, Spinolo J, Zon G (1992) Guest editorial: systemic human antisense therapy begins. Antisense Res Dev 2:109–110
Smith LJ, McCulloch EA, Benchimol S (1986) Expression of the p53 oncogene in acute myeloblastic leukemia. J Exp Med 164:71–76
Maher LJ, Dolnick BJ (1987) Specific hybridization arrest of dihydrofolate reductase mRNA in vitro using anti-sense RNA or anti-sense oligonucleotides. Arch Biochem Biophys 253:214–220
Walder RY, Walder JA (1988) Role of RNase H in hybrid-arrested translation by antisense oligonucleotides. Proc Natl Acad Sci USA 85:5011–5015
Loke SL, Stein C, Zhang XH, Mori K, Nakanishi M, Subasinghe C, Cohen JS, Neckers LM (1989) Characterization of oligonucleotide transport into living cells. Proc Natl Acad Sci USA 86:3474–3478
Yakubov LA, Deeva EA, Zarytova VF, Ivanova EM, Ryte AS, Yurchenko LV, Vlassov VV (1989) Mechanism of oligonucleotide uptake by cells: involvement of receptors? Proc Natl Acad Sci USA 86:6454–6458
Stein CA, Tonkinson JL, Zhang LM, Yakubov L, Gervasoni J, Taub R, Rosenberg SA (1993) Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry 32:4855–4861
Akhtar S, Shoji Y, Juliano RL (1992) Pharmaceutical aspects of the biological stability and membrane transport characteristics of antisense. In: Erickson RP, Izant JG (eds) Gene regulation: biology of antisense RNA and DNA, vol 1. Raven, New York, 133–145
Shaw JP, Kent K, Bird J, Fishback J, Froehler B (1991) Modified deoxyoligonucleotides stable to exonuclease degradation in serum. Nucleic Acids Res 19:747–750
Letsinger RL, Zhang G, Sun DK, Ikeuchi T, Sarin PS (1989) Cholesteryl-conjugated oligonucleotides: synthesis, properties and activity as inhibitors of replication of human immunodeficiency virus in culture. Proc Natl Acad Sci USA 86:6553–6556
Clarence JP, Degols G, Leonetti JP, Milhaud P, Lebleu B (1993) Delivery of antisense oligonucleotides by poly (l-lysine) conjugation and liposome encapsulation. Anti-Cancer Drug Design 8:81–94
Leonetti JP, Machy, P, Degols G, Lebleu B, Leserman L (1990) Antibody-targeted liposomes containing oligdeoxyonu-cleotides complementary to viral RNA selectively inhibit viral replication. Proc Natl Acad Sci USA 87:2448–2451
Milligan JF, Jones RJ, Froehler BC, Matteucci MD (1994) Development of antisense therapeutics: implications for cancer gene therapy. Ann NY Acad Sci 716:228–241
Eguchi Y, Itoh T, Tomizawa J (1991) Antisense RNA. Annu Rev Biochem 60:631–652
Krystal GW (1992) Regulation of eukaryotic gene expression by naturally occurring antisense RNA. In: Erickson RP, Izant JG (eds) Gene regulation: biology of antisense RNA and DNA, vol 1. Raven, New York, 11–20
Inouye M (1988) Antisense RNA its function and applications in gene regulation — a review. Gene 72:25–34
Weintraub HM (1990) Antisense RNA and DNA. Sci Am 262:40–48
Ledwith BJ, Manam S, Kraynak AR, Nichols WW, Bradley MO (1990) Antisense-fos RNA causes partial reversion of the transformation phenotypes induced by the c-Ha-ras oncogene. Mol Cell Biol 10:1545–1555
Sklar MD, Thompson E, Welsh MJ, Liebert M, Harney J, Grossman HB, Smith M, Prochownik EV (1991) Depletion of c-myc with specific antisense sequences reverses the transformed phenotype in ras oncogene-transformed NIH 3T3 cells. Mol Cell Biol 11:3699–3710
Mukhopadhyay T, Tainsky M, Cavender AC, Roth JA (1991) Specific inhibition of K-ras expression and tumorigenicity of lung cancer cells by antisense RNA. Cancer Res 51:1744–1748
Skotzko M, Wu L, Anderson WF, Gordon EM, Hall FL (1995) Retroviral vector-mediated gene transfer of antisense cyclin G1 (CYCG1) inhibits proliferation of human osteogenic sarcoma cells. Cancer Res 55:5493–5498
Kibler-Herzog L, Kell B, Zon G, Shinozuka K, Miizan S, Wilson WD (1990) Sequence-dependent effects in methylphosphonate deoxyribonucleotide double and triple helical complexes. Nucleic Acids Res 18:3545–3555
Maher LJ, Wold B, Dervan PB (1989) Inhibition of DNA binding proteins by oligonucleotide-directed triple helix formation. Science 245:725–730
Hanvey JC, Shimizu M, Wells RD (1990) Site-specific inhibition of Eco-RI restriction/modification enzymes by a DNA triple helix. Nucleic Acids Res 18:157–161
Cooney M, Czernuszewicz G, Postel EH, Flint SJ, Hogan ME (1988) Site-specific oligonucleotide binding represses transcription of the human c-myc gene in vitro. Science 241:456–459
Orson FM, Thomas DW, McShan WM, Kessler DJ, Hogan ME (1991) Oligonucleotide inhibition of IL2Ra RNA transcription by promoter region collinear triplex formation in lymphocytes. Nucleic Acids Res 19:3435–3441
Gee JE, Miller DM (1992) Structure and applications of inter-molecular DNA triplexes. Am J Med Sci 304:366–372
Ono A, Ts′o OP, Kan LS (1991) Triplex formation of oligonucleotides containing 2′-O-methylpseudo-isocytidine in substitution for 2′-deoxycidine. J Am Chem Soc 113:4032–4033
Gagnor C, Bertrand JR, Thenet S, Lemaitre M, Morvan F, Rayner B, Malvy C, Lebleu B, Imbach JL, Paoletti C (1987) Comparative study of α and β anomeric oligdeoxy-ribonucleotides in hybridization to mRNA and in cell-free translation inhibition. Nucleic Acids Res 15:10507–10521
Helene C (1992) Control of gene expression by antisense and antigene oligonucleotide-intercalator conjugates. In: Erickson RP, Izant JG (eds) Gene regulation: biology of antisense RNA and DNA, vol 1. Raven, New York, 109–118
Kim SH, Cech TR (1987) Three-dimensional model of the active site of the self-splicing rRNA precursor of tetrahymena. Proc Natl Acad Sci USA 84, 8788–8792
Cech TR (1988) Ribozymes and their medical implications. JAMA 260:3030–3034
von Ahsen U, Schroeder R (1993) RNA as a catalyst: natural and designed ribozymes. Bioessays 15:299–307
Kashani-Sabet M, Funato T, Tone T, Jiao L, Wang W, Yoshida E, Kashfinn BI, Shitara T, Wu AM, Moreno JG, Traweek ST, Ahlering TE, Scanlon KJ (1992) Reversal of the malignant phenotype by an anti-ras ribozyme. Antisense Res Dev 2:3–15
Koizumi M, Kamiya H, Ohtsuka E (1992) Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene. Gene 117:179–184
Sioud M, Natvig JB, Forre O (1992) Preformed ribozyme destroys tumour necrosis factor mRNA in human cells. J Mol Biol 223:831–835
Weerasinghe M, Liem SE, Asad S, Read SE, Joshi S (1991) Resistance to human immunodeficiency virus type 1 (HIV-1) infection in human CD4+ lymphocyte-derived cell lines conferred by using retroviral vectors expressing an HIV-1 RNA-specific ribozyme. J Virol 65:5531–5534
Lu D, Chtterjee S, Brar D, Wong KK, Jr (1994) Ribozymemediated in vitro cleavage of transcripts arising from the major transforming genes of human papillomavirus type 16. Cancer Gene Ther 1267–277
Zhang Y, Mukhopadhyay T, Donehower LA, Georges RN, Roth JA (1993) Retroviral vector-mediated transduction of K-ras antisense RNA into human lung cancer cells inhibits expression of the malignant phenotype. Human Gene Ther 4:451–460
Georges RN, Mukhopadhyay T, Zhang Y, Yen N, Roth JAL (1993) Prevention of orthotopic human lung cancer growth by intratracheal instillation of a retroviral antisense K-ras construct. Cancer Res 53:1743–1746
McLemore TL, Liu MC, Blacker PC, Gregg M, Alley MC, Abbott BJ, Shoemaker RH, Bohlman ME, Litterst CC, Hubbard WC, Brennan RH, McMahon JB, Fine DL, Eggleston JC, Mayo JG, Boyd MR (1987) Novel intrapulmonary model for orthotopic propagation of human lung cancers in athymic nude mice. Cancer Res 47:5132–5140
Alemany R, Ruan S, Koch PE, Mukhopadhyay T, Roth JA, Zhang W-W (1996) Growth inhibitory effect of anti-K-ras adenovirus on lung cancer cells. Cancer Gene Ther (in press)
Harris H (1993) How tumor suppressor genes were discovered. FASEB J 7:978–979
Anderson MJ, Stanbridge EJ (1993) Tumor suppressor genes studied by cell hybridization and chromosome transfer. FASEB J 7:826–833
Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A (1992) Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumors. Nature 356:215–221
Duan DR, Pause A, Burgess WH, Aso T, Chen DYT, Garrett KP, Conaway RC, Conaway JW, Linehan WM, Klausner RD (1995) Inhibition of transcription elongationby the VHL tumor suppressor protein. Science 269:1402–1406
Wiman KG (1993) The retinoblastoma gene: role in cell-cycle control and cell differentiation. FASEB J 7:841–845
Huang HJS, Yee JK, Shew JY, Chen PL, Bookstein R, Friedmann T, Lee EYHP, Lee WH (1988) Suppression of the neoplastic phenotype by replacement of the RB gene in human cancer cells. Science 242:1563–1566
Bookstein R, Shew JY, Chen PL, Scully P, Lee WH (1990) Suppression of tumorigenicity of human prostate carcinoma cells by replacing a mutated RB gene. Science 247:712–715
Montenarh M (1992) Biochemical, immunological, and functional aspects of the growth-suppressor/oncoprotein p53. Crit Rev Oncogene 3:233–256
Tominaga O, Hamelin R, Remvikos Y, Salmon RJ, Thomas G (1992) p53 from basic research to clinical applications. Crit Rev Oncogene 3:257–282
Mercer WE (1992) Cell-cycle regulation and the p53 tumor suppressor protein. Crit Rev Eukaryot Gene Expr 2:251–263
Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB (1992) Wild-type p53 is a cell-cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA 89:7491–7495
Fields S, Jang SJ (1990) Presence of a potent transcription-activating sequence in the p53 protein. Science 249:1046–1049
Mietz JA, Unger T, Huibregtse JM, Howley PM (1992) The transcriptional transactivation function of wild-type p53 is inhibited by SV40 large T-antigen and by HPV-16 E6 oncoprotein. EMBOJ 11:5013–5020
Wilcock D, Lane DP (1991) Localization of p53, retinoblastoma, and host replication proteins at sites of viral replication in herpes-infected cells. Nature 349:429–431
Bargonetti J, Friedmann PN, Kern SE, Vogelstein B, Prives C (1991) Wild-type but not mutant p53 immunopurified proteins bind to sequences adjacent to the SV40 origin of replication. Cell 65:1083–1091
Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M (1991) Wild-type p53 induces apoptosis of myeloid leukemic cells that is inhibited by interleukin-6. Nature 352:345–347
Shaw P, Bovey R, Tardy S, Sahli R, Sordat B, Costa J (1992) Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. USA 89:4495–4499
Ryan JJ, Danih R, Gottlieb CA, Clarke, M (1993) Cell-cycle analysis of p53-induced cell death in murine erythroleukemia cells. Mol Cell Biol 13:711–719
Finlay CA, Hinds PW, Levine AJ (1989) The p53 proto-oncogene can act as a suppressor of transformation. Cell 57:1083–1093
Baker SJ, Markowitz S, Fearson ER, Villson JKV, Vogelstein B (1990) Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249:912–915
Cheng J, Yee JK, Yeargin J, Friedmann T, Haas M (1992) Suppression of acute lymphoblastic leukemia by the human wild-type p53 gene. Cancer Res 52:222–226
Takahashi T, Carbone D, Takahashi T, Nau MM, Hida T, Linnoila I, Ueda R, Minna JD (1992) Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res 52:2340–2343
Quinlan DC, Davidson AG, Summers CL, Warden HE, Doshi HM (1992) Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52:4828–4831
Horio Y, Takahashi T, Kuroishi T, Hibi K, Suyama M, Niimi T (1993) Prognostic significance of p53 mutations and 3P deletions in primary resected non-small cell lung cancer. Cancer Res 53:1–4
Shrivastova S, Zou A, Pirollo K, Blattner S, Chang E (1990) Germline transmission of a mutated p53 gene in a cancer prone family with Li-Fraumeni syndrome. Nature 348:747–749
Harper JW, Adam GR, Wei N, Keyomarsi K, Elledge SJ (1993) The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinase. Cell 75:805–816
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzier KW, Vogelstein B (1993) WAF1, a potential mediator of p53 tumor suppression. Cell 75:817–825
Roemer K, Friedmann T (1994) Mechanisms of action of the p53 tumor suppressor and prospects for cancer gene therapy by reconstitution of p53 function. Ann NY Acad Sci 716:265–280
Goyette MC, Cho K, Fasching CL, Levy DB, Kinzler KW, Paraskeva C, Vogelstein B, Stanbridge EJ (1992) Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol 12:1387–1395
Leone A, Flatow U, King CR, Sandeen MA, Margulies MK, Liotta LA, Steeg PS (1991) Reduced tumor incidence, metastatic potential, and cytokine responsiveness of nm23-transfected melanoma cells. Cell 65:25–35
Florenes VA, Aamdal S, Myklebost O, Maelandsmo GM, Bruland OS, Fodstad O (1992) Levels of nm23 messenger RNA in metastatic melanomas inverse correlation to disease prognosis. Cancer Res 52:6088–6091
Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS III, Johnson BE, Skolnick MH (1994) A cell cycle regulator potentially involved in genesis of many tumor types. Science 264:436–440
Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA (1994) Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368:753–756
Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, Bell R, Rosenthal J, Hussey C, Tran T, McClure M, Frye C, Hattier T, Phelps R, Haugen-Strano A, Katcher H, Yakumo K, Gholami Z, Shaffer D, Stone S, Bayer S, Wray C, Bogden R, Dayananth P, Ward J, Tonin P, Narod S, Bristow PK, Norris FH, Helvering L, Morrison P, Rosteck P, Lai M, Barrett JC, Lewis C, Neuhausen S, Cannon-Albright L, Goldgar D, Wiseman R, Kamb A, Skolnick MH (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266:66–71
Hannon G, Beach D (1994) p15INK4B is a potential effector of TGF-induced cell cycle arrest. Nature 371:257–261
Marx J (1994) A challenge to p16 gene as a major tumor suppressor. Science 264, 1846
Zhang S-Y, Klein-Szanto AJP, Sauter ER, Shafarenko M, Mitsunaga S, Nobori T, Carson DA, Ridge JA, Goodrow TL (1994) Higher frequency of alternations in the p16/CDKN2 gene in squamous cell carcinoma cell lines than in primary tumors of the head and neck. Cancer Res 54:5050–5053
Jen J, Harper W, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JKV, Kinzler KW, Vogelstein B (1994) Deletion of p16 and p15 genes in brain tumors. Cancer Res 54:6353–6358
Washimi, O, Nagatake, M, Osada, H, Ueda, R, Koshikawa, T, Seki, T, Takahashi, T, Takahashi, T (1995) In vivo occurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 55:514–517
Hussussian CJ, Struewing JP, Goldstein AM, Higgins PAT, Ally DS, Sheahan MD, Clark WH Jr, Tucker MA, Dracopoli NC (1994) Germline p16 mutation in familial melanoma. Nature Genet 8:15–21
Cai DW, Mukhopadhyay T, Liu Y, Fujiwara T, Roth JA (1993) Stable expression of the wild-type p53 gene in human lung cancer cells after retrovirus-mediated gene transfer. Hum Gene Ther 4:617–624
Fujiwara T, Grimm EA, Mukhopadhyay T, Cai DW, Owen-Schaub LB, Roth JA (1993) A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis. Cancer Res 53:4129–4133
Casson AG, Mukhopadhyay T, Cleary KR, Ro JY, Levine B, Roth JA (1991) p53 mutations in Barrett's epithelium and esophageal cancer. Cancer Res 51:4495–4499
Chung KY, Mukhopadhyay T, Kim J, Casson A, Ro JY, Goepfert H, Hong WK, Roth JA (1993) Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the aerodigestive tract. Cancer Res 53:1676–1683
Zhang W-W, Fang X, Branch CD, Mazur W, French BA, Roth JA (1993) Generation and identification of recombinant adenovirus by liposome-mediated transfection and PCR analysis. Biotechniques 15:868–872
Zhang W-W, Fang X, Mazur W, French BA, Georges RN, Roth JA (1994) High-efficiency gene transfer and high-level expression of wild-type p53 in human lung cancer cells mediated by recombinant adenovirus. Cancer Gene Ther 1:5–13
Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA (1994) Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54:2287–2291
Wang J, Bucana CD, Roth JA, Zhang W-W (1995) Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53. Cancer Gene Ther 1:9–17
Wills KN, Maneval DC, Menzel P, Harris MP, Sutjipto S, Vaillancourt M-T, Huang W-M, Johnson DE, Anderson SC, Wen SF, Bookstein R, Shepard HM, Gregory RJ (1994) Development and characterization of recombinant adenoviruses encoding human p53 for gene therapy of cancer. Hum Gene Ther 5:1079–1088
Liu TJ, Zhang W-W, Taylor DL, Roth JA, Goepfert H, Clayman GL (1994) Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 54:3662–3667
Dulic V, Kaufman, WK, Wilson S, Tisty TD, Lees E, Harper JW, Elledge SJ, Reed SI (1994) p53-dependent inhibition of cyclin dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76:1013–1023
Sherr CJ, Roberts JM (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149–1163
El-Diery WS, Harper JW, Oconnor PM, Velculesca VE, Canman CE, Jackman J, Pietenpol J, Burrell M, Hill DE, Mercer WE, Kastan MB, Kohn KW, Elledge SJ, Kinzler KW, Vogelstein B (1994) WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res 54:1169–1174
Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai L-H, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, Fox MP, Wei N (1995) Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell 6:387–400
Deng C, Zhang P, Harper JW, Elledge SJ, Leder P (1995) Mice deficient in p21 develop normally but have defects in G1 checkpoint function. Cell 82:675–684
Gossen M, Bujard H (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89:5547–5551
Chen TQ, Cipriano SC, Arenkiel JM, Miller FR (1995) Tumor suppression by p21WAF1. Cancer Res 55:4536–4539
Katayose D, Wersto R, Cowan KH, Seth P (1995) Effects of a recombinant adenovirus expressing WAF1/Cip1 on cell growth, cell cycle, and apoptosis. Cell Growth Diff 6:1207–1212
Eastham JA, Hall SJ, Sehgal I, Wang J, Timme TL, Yang G, Connell-Crowley L, Elledge SJ, Zhang W-W, Harper JW, Thompson TC (1995) In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res 55:5151–5155
Serrano M, Hannon GJ, Beach D (1993) A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond) 366:704–707
Serrano M, Gomez-Lahoz E, Depinho RA, Beach D, BarSagi D (1995) Inhibition of ras-induced proliferation and cellular transformation by p16INK14. Science 267:249–252
Caldas C, Hahn SA, Dacosta LT, Redston MS, Schutte M, Seymour AB, Weinstein CL, Hruban RH, Yeo CJ, Kern SE (1994) Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 8:27–32
Cheng JQ, Jhanwar SC, Llein WM, Bell DW, Lee W, Altomare DA, Nobori T, Olopade OI, Buckler AJ, Testa JR (1994) p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. Cancer Res 54:5547–5551
Kamb A, Shattuck-Eidens D, Liu Q, Gruis NA, Ding W, Hussey C, Tran T, Miki Y, Weaver-Felkhous J, McClure M, Atiken JF, Anderson DE, Hergman W, Frants R, Goldgar DE, Green A, MacLennan R, Martin NG, Meyer LJ, Youl P, Zone JJ, Skolnick MH, Cannon-Albright LA (1994) Analysis of the p16 gene (CDKN2) as a candidate from chromosome 9p melanoma susceptifility locus. Nature Genet 8:22–26
Mori T, Miura K, Aoki T, Nishihira T, Mori S, Nakamura Y (1994) Frequent somatic mutation of the MTS1/CDK41 (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) gene in esophageal squamous cell carcinoma. Cancer Res 54:3396–3397
Okamoto A, Demetrick DJ, Spillare EA, Higiwara K, Hussain SP, Bennett WP, Forrester K, Gerwin B, Serrano M, Beach DH, Harris CC (1994) Mutations and altered expression pf p16(INK4) in human cancer. Proc Natl Acad Sci USA 91:11045–11049
Orlow I, Lianes P, Lacombe L, Dalbagni G, Reuter VE, Cardon-Cardo C (1994) Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors. Cancer Res 54:2848–2851
Arap W, Nishikawa R, Furnari FB, Cavenee WK, Huang HS (1995) Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res 55:1351–1354
Jin X, Nguyen D, Zhang W-W, Kyritsis AP, Roth JA (1995) Cell cycle arrest and inhibition of tumor cell proliferation by the p16 INK4 gene mediated by an adenovirus vector. Cancer Res 55:3250–3253
Takahashi T, Nau MM, Chiba I, Birrer MJ, Rosenberg RK, Vinocour M, Levitt M, Pass H, Gazdar AF, Minna JD (1989) p53: a frequent target for genetic abnormalitits in lung cancer. Science 246:491–494
Harbour JW, Lai S, Whang-Peng J, Gazdar AF, Minna JD, Kaye FJ (1988) Abnormalities instructure and expression of the human retinoblastoma gene in SCLC. Science 241:353–357
Mitsudomi T, Steinberg SM, Nau MM, Carbone D, DÕAmico D, Bodner S, Oie HD, Linnoila RI, Mulshine JL, Minna JD, Gazdar AF (1992) p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7:171–180
Fujiwara T, Cai DW, Georges RN, Mukhopadhay T, Grimm EA, Roth JA (1994) Therapeutic effect of a retroviral wildtype p53 expression vector in an orthotopic lung cancer model. J Natl Cancer Inst 86:1458–1462
Culver KW, Ram Z, Wallbridge S, Ishii H, Oldfield EH, Blaese, RM (1992) Vector-producer cells for treatment of experimental brain tumors. Science 256:1550–1552
Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T (1993) p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847–849
Hu G, Liu W, Hanania EG, Fu S, Wang T, Deisseroth AB (1995) Suppression of tumorigenesis by transcription units expressing the antisense E6 and E7 messenger RNA (mRNA) for the transforming proteins of human papilloma virus and the sense mRNA for the retinoblastoma gene in cervical carcinoma cells. Cancer Gene Ther 2:19–32
Castleden S, Helson JA, Chong H, Hart I, Vile RG (1995) The use of combination gene therapies for the treatment of cancer. J Cell Biochem 21 [Suppl A]:418
Chen SH, Chen XH, Kosail KI, Wang Y, Finegold MJ, Rich SS, Woo SLC (1995) Combination suicide and cytokine gene therapy for metastatic colon carcinoma in vivo. J Cell Biochem 21 [Suppl A]:419
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Zhang, W.W. Antisense oncogene and tumor suppressor gene therapy of cancer. J Mol Med 74, 191–204 (1996). https://doi.org/10.1007/BF00204749
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00204749